Profound Medical's TULSA Procedure Shows Superior Penile Length Preservation vs. Surgery in CAPTAIN Trial
PROF sits 86% above its 52-week low of $3.76.
Summary
Profound Medical announced new CAPTAIN trial data showing TULSA preserved penile length with no median change at 1 month, while robotic surgery caused a 0.65 cm reduction — a statistically significant difference. The results reinforce TULSA's quality-of-life advantages over surgery.
Key Events · Product Development and Regulatory · PROF
-
Superior Penile Length Preservation
At 1 month post-treatment, TULSA showed no median change in penile length versus a 0.65 cm reduction after robotic RP (p<0.001).
-
Builds on Prior Quality-of-Life Wins
This follows previously announced CAPTAIN primary safety results, where TULSA demonstrated statistically significant superiority in preserving erectile function and urinary continence at 6 months.
-
CAPTAIN Trial Design and Status
The prospective, multi-center RCT enrolled 211 patients with intermediate-risk prostate cancer; the primary safety endpoint is at 1 year, efficacy at 3 years. Data were presented at SRS 2026.
-
Commercial Implications
Consistent quality-of-life advantages could accelerate TULSA adoption as a differentiated, incision-free alternative to surgery, supporting the revenue growth trajectory.
Analysis · PROF · Industrial Applications And Services
Fresh Level 1 randomized trial data reveal that TULSA ablation preserves penile length significantly better than robotic prostatectomy at one month — a meaningful quality-of-life differentiator that could strengthen commercial adoption. The CAPTAIN trial, a pivotal post-market study comparing TULSA to the surgical standard of care, now adds these results to previously reported superiority in erectile function and urinary continence. While the data are early (1-month follow-up) and the primary endpoints sit at 1 and 3 years, the consistent pattern of better functional outcomes builds a compelling case for TULSA as a first-line option in intermediate-risk prostate cancer.
How filings like this one have moved
In the 30 days to Sep 30, 2026, 29.5% of the 1626 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PROF was trading at $7.00 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $254.4M. The 52-week trading range was $3.76 to $8.95. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.